Filing Flows › Xtant Medical Holdings (XTNT) › Orthobiologics revenue
Xtant Medical Holdings (XTNT) Orthobiologics revenue by quarter
Xtant Medical Holdings' Orthobiologics revenue was $17.4M in Q2 2026 (second quarter 2026), +11% from Q1 2026. Over the last 6 quarters it ranged from $15.6M (Q1 2026) to $19.4M (Q2 2025).
| Quarter | Orthobiologics revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $17.4M | +11% | -10% |
| Q1 2026 | $15.6M | -15% | -14% |
| Q4 2025 | $18.3M | +7% | — |
| Q3 2025 | $17.1M | -11% | — |
| Q2 2025 | $19.4M | +7% | — |
| Q1 2025 | $18.1M | — | — |
Q2 2026 at a glance
Xtant Medical Holdings, Q2 2026: revenue $23.0M (-35% year over year), operating margin -39.8%, net loss $9.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xtant Medical Holdings' Orthobiologics revenue?
Xtant Medical Holdings' Orthobiologics revenue was $17.4M in Q2 2026 (second quarter 2026), +11% from Q1 2026.
How has Xtant Medical Holdings' Orthobiologics revenue changed?
Over the last 6 quarters it ranged from $15.6M (Q1 2026) to $19.4M (Q2 2025).
Q2 2026 results → · How Xtant Medical Holdings makes money →